Ann: Echosolv Collaboration Agreement with Mayo Clinic Platform, page-3

Total addressable market in the US is US$70Bn

§ Meeting with FDA provided Echo IQ with a clear path to gain regulatory clearance for EchoSolv HF

§ Agreement includes potential for licencing of EchoSolv HF to 30 Mayo Clinic Care Network sites using the group’s proprietary integration software system for a three-year period

§ Validation study expected to commence this quarter with FDA clearance anticipated H2 CY2025

Developments follow two completed studies using EchoSolv HF which demonstrated:

o EIQ’s AI standalone performance detected 86% of heartfailure cases (vs 46% detection in standard clinical practice)

o AI and clinical evaluation combined increased accuracyto 97% in high-risk individuals

…..not to mention the phenomenal increase in efficiencycutting diagnosis from days to hours…